Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200519047510N1

Enrollment

Registered

2020-05-28

Start date

2020-06-05

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Corona virus infection, unspecified

Interventions

Intervention 1: Intervention group: receiving 3 nanocurcumin 80 mg capsules (240 mg) for 7 days at the same time with common therapeutic protocol. Intervention 2: Control group: received common therap

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Confirmed COVID-19 infection Conscious consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Long-term use of immunosuppressive drugs Use of nutritional supplements Dissatisfaction to participate in the study

Design outcomes

Primary

Measure	Time frame
Gene expression of inflammatory cytokines in peripheral blood mono-nuclear cells of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: real time-PCR.;Serum levels of inflammatory cytokines of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: ELISA technique.;Clinical symptoms of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Examination by a specialist.;Laboratory findings of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Laboratory findings in the Patient file.	—

Measure

Time frame

Gene expression of inflammatory cytokines in peripheral blood mono-nuclear cells of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: real time-PCR.;Serum levels of inflammatory cytokines of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: ELISA technique.;Clinical symptoms of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Examination by a specialist.;Laboratory findings of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Laboratory findings in the Patient file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Asadirad

Ahvaz University of Medical Sciences

ali.asadirad@sbmu.ac.ir+98 61 3332 2316

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026